@article {8209,
	title = {Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatinum-based chemotherapy},
	journal = {Journal of Urology},
	volume = {151},
	year = {1994},
	note = {Cited By :45Export Date: 21 February 2017},
	month = {1994},
	pages = {598 - 601},
	abstract = {Cis-platinum-based chemotherapy combinations have improved the outcome of patients with metastatic urothelial tumors, since two-thirds of these patients respond to treatment. Nevertheless, the majority of such patients have relapse within a median of 12 months. To define the pattern of failure and subsequent outcome, we retrospectively assessed 58 consecutive patients with relapse after prior response to cis-platinum-based combination chemotherapy. Of the patients who presented initially with local-regional metastases, 74\% had relapse with involvement of a similar site, while only 26\% of these patients had visceral metastases at relapse. The median survival after relapse was 9 months, and parameters associated with longer survival were local-regional relapse (10.7 months) and response to salvage chemotherapy (12.6 months). These data suggest that select patients with urothelial tumors and local-regional metastases may benefit from consolidation therapy with surgery or radiotherapy after maximum response to chemotherapy.},
	keywords = {Bladder neoplasms, Cisplatin, Drug Therapy, Recurrence, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028089224\&partnerID=40\&md5=abb445ae32e6e88184ac18b997d2e86b},
	author = {Dimopoulos, M.A. and Finn, L. and Logothetis, C. J. and Droller, M.J. and Yagoda, A.}
}
